The hepatitis C revolution part 1: antiviral treatment options

@article{Thiagarajan2015TheHC,
  title={The hepatitis C revolution part 1: antiviral treatment options},
  author={Prarthana Thiagarajan and Stephen D. Ryder},
  journal={Current Opinion in Infectious Diseases},
  year={2015},
  volume={28},
  pages={563–571}
}
Purpose of review The rapid evolution in the therapeutic landscape of hepatitis C presents a minefield to clinicians seeking to optimize therapy for their patients. Efficacy, evidence-base, side-effects, and drug combinations must be tailored to individual patients, taking into account comorbidities, degree of fibrosis, evidence of hepatic decompensation, and life expectancy. The review article aims to discuss novel hepatitis C virus (HCV) treatments with an overview of recent breakthrough… Expand
On the Possibility of Eradicating Hepatitis C in Russia
Long-term efforts of the international community led to the development of highly efficient direct-acting antivirals (DAAs) that allow treatment of the vast majority of patients with chronicExpand
Nuevos progresos en el enfrentamiento a la hepatitis C
TLDR
The fast development of new therapies against hepatitis C has led to more efficacious methods with less adverse reactions, optimizing the treatment of these patients. Expand
Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
TLDR
Exposure‐response analysis supports the clinical utility of the combination regimen of 60‐mg once‐daily DCV and 100‐mg twice‐daily ASV in Japanese patients infected with HCV GT 1b. Expand
Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong
TLDR
DAA-based treatments are cost-effective alternatives to INF-based treatment in Hong Kong and resulting in a 126.1% budget increase on HCV infection management over 5 years is still economically favorable to the local government. Expand
Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals
TLDR
The implementation of a pharmaceutical care program in patients with hepatitis C treated with direct-acting antivirals has improved the safety in the use of these drugs. Expand
Exposure‐Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Patients
TLDR
Overall, the E‐R model was developed that captured the high SVR12 rates and the effect of covariates for the 3DAA regimen in HCV‐infected patients. Expand
Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct‐acting antivirals: The GRUviC project
TLDR
The implementation of a comprehensive pharmaceutical care programme for HCV‐infected patients treated with direct‐acting antivirals in a tertiary‐care hospital is described and data about health outcomes and costs is provided. Expand
Evolution of matrinic ethanol derivatives as anti-HCV agents from matrine skeleton.
TLDR
This study provided powerful information on further strategic optimization and development of 12N-substituted matrinic ethanol derivatives into a novel family of anti-HCV agents. Expand
Hepatitis C core antigen highly correlated to HCV RNA
TLDR
Analysis of 221 anti‐HCV‐positive patient sera found a strong positive correlation between HCV RNA and HCV‐Ag, and it is proposed that HCV •Ag immunoassay is a more cost and time efficient alternative to the current two‐step diagnostic process. Expand
Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation
TLDR
Graft survival was excellent up to a DS of 2, however a DS >2 should be avoided in higher-risk recipients, andHypothermic oxygenated machine perfusion can be applied clinically in DCD liver grafts, and Feasibility and safety were confirmed. Expand
...
1
2
...

References

SHOWING 1-10 OF 56 REFERENCES
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop
TLDR
To provide an overview of the current knowledge of the mechanisms of action of IFN-α and ribavirin against HCV and offer guidance for future research, the American Association for the Study of Liver Diseases held a single topic conference on March 1-3, 2007. Expand
Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV)
TLDR
This review will summarize current management for chronic HCV infection, anticipating the approval of additional IFN-free regimens with comparable efficacy and tolerability but with the addition of pangenotypic coverage, fewer drug-drug interactions, and a high barrier to resistance. Expand
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
TLDR
Asunaprevir is a good candidate component of interferon-free combinations and may revolutionize the treatment of chronic HCV infection in the near future. Expand
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
  • D. Wyles
  • Medicine
  • The Journal of infectious diseases
  • 2013
TLDR
Progress in the development of other HCV antivirals, such as NS5A inhibitors, next-generation NS3 protease inhibitors, and NS5B nucleoside and nonnucleoside inhibitors, has provided a broad selection of potent antiviral such that interferon-free therapy is a reality. Expand
Expert opinion on the treatment of patients with chronic hepatitis C
TLDR
Potential approaches for the optimization of treatment for patients with HCV genotype 1 are explored, considering shorter treatment periods for Patients with a rapid virological response (RVR), increasing treatment period for slow responders, and increasing RBV dose are all suggestions. Expand
Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?
TLDR
None of the proposed mechanisms of action convincingly explains RBV-mediated potentiation of IFN-based therapy in HCV-infected patients and, although they are not mutually exclusive, they are all still a matter of controversy. Expand
Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings.
TLDR
The use of oral DAAs has the potential to provide treatment at scale by offering opportunities to simplify drug regimens, laboratory requirements, and service delivery models, and key desirable characteristics of future HCV treatment regimens include high efficacy, tolerability, pan-genotype activity, short treatment duration, oral therapy, affordability, and availability as fixed-dose combination. Expand
NS5A inhibitors in the treatment of hepatitis C.
TLDR
Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens. Expand
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
TLDR
A post‐hoc analysis of data from seven clinical trials suggests that 12 weeks of LDV‐SOF is safe and effective for treatment‐naïve patients with HCV genotype 1 and compensated cirrhosis. Expand
Novel therapies for hepatitis C — one pill fits all?
TLDR
The current and upcoming treatment options for HCV are reviewed, the key challenges facing clinicians and drug developers are described and how the landscape in the HCV arena will change over the coming years are discussed. Expand
...
1
2
3
4
5
...